Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Preeclampsia is associated with significant maternal and fetal morbidity and mortality. Early
identification and subsequent management of patients at risk of developing preeclampsia
presents an ongoing challenge in prenatal care. Some at risk pregnancies may be identified
from:
- serum screening abnormalities in the first or second trimester
- placental shape and texture at the 18-20 anatomical ultrasound
- uterine artery blood flow.
Early identification and effective treatment of patients would permit the safe completion of
the pregnancy for the mother and infant. Recent advances in non-invasive cardiovascular
monitoring have enabled the study of maternal hemodynamics in normal and at-risk pregnancies.
This study hopes to identify the earliest significant changes in maternal hemodynamics which
may allow targeted therapeutic interventions in patients at high risk of developing
preeclampsia.
The hypothesis of this study is that systemic vascular resistance rises during the
pre-clinical phase of preeclampsia and this can be captured using non invasive bioreactance
technology. Treatment of the abnormally high vascular tone may decrease the severity and
postpone the onset of clinical disease.
Phase:
N/A
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital